Financial Ratios Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
14.95 ^USD	+5.58%		+10.82%	+66.30%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

c01a4fcaafdccdd.DqUP16jXVymPVPCqYsfMSZfVYitHe9BuSdm10056yXc.WcZGkuqbH0H5H4LyBv6KGdqjVxk1EuNaHInTni9PgkN6iH28hbtgUeUxpQ

Published financial data: INTELLIA THERAPEUTICS, INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	33.05M	52.12M	36.28M	57.88M	67.67M
Total Revenues	33.05M	52.12M	36.28M	57.88M	67.67M
Cost of Goods Sold, Total	220M	420M	435M	466M	324M
Gross Profit	-187M	-368M	-399M	-408M	-257M
Selling General & Admin Expenses, Total	71.1M	90.31M	116M	126M	184M
Other Operating Expenses, Total	71.1M	90.31M	116M	126M	184M
Operating Income	-258M	-458M	-515M	-534M	-441M
Interest And Investment Income	1.28M	8.54M	49.83M	47.81M	29.2M
Net Interest Expenses	1.28M	8.54M	49.83M	47.81M	29.2M
Income (Loss) On Equity Invest.	-1.32M	-11.08M	-15.63M	-	-
EBT, Excl. Unusual Items	-258M	-461M	-481M	-486M	-412M
Gain (Loss) On Sale Of Investments	-	-	-	-32.56M	-899K
Other Unusual Items	-10M	-13.48M	-100K	-	-
EBT, Incl. Unusual Items	-268M	-474M	-481M	-519M	-413M
Earnings From Continuing Operations	-268M	-474M	-481M	-519M	-413M
Net Income to Company	-268M	-474M	-481M	-519M	-413M
Net Income - (IS)	-268M	-474M	-481M	-519M	-413M
Net Income to Common Incl Extra Items	-268M	-474M	-481M	-519M	-413M
Net Income to Common Excl. Extra Items	-268M	-474M	-481M	-519M	-413M
Per Share Items
Net EPS - Basic	-3.78	-6.16	-5.42	-5.25	-3.81
Basic EPS - Continuing Operations	-3.78	-6.16	-5.42	-5.25	-3.81
Basic Weighted Average Shares Outstanding	70.89M	76.97M	88.77M	98.85M	108M
Net EPS - Diluted	-3.78	-6.16	-5.42	-5.25	-3.81
Diluted EPS - Continuing Operations	-3.78	-6.16	-5.42	-5.25	-3.81
Diluted Weighted Average Shares Outstanding	70.89M	76.97M	88.77M	98.85M	108M
Normalized Basic EPS	-2.27	-3.74	-3.39	-3.08	-2.37
Normalized Diluted EPS	-2.27	-3.74	-3.39	-3.08	-2.37
Supplemental Items
EBITDA	-251M	-451M	-506M	-524M	-431M
EBITA	-258M	-458M	-515M	-534M	-441M
EBIT	-258M	-458M	-515M	-534M	-441M
EBITDAR	-235M	-428M	-473M	-486M	-367M
Normalized Net Income	-161M	-288M	-301M	-304M	-257M
Supplemental Operating Expense Items
General and Administrative Expenses	71.1M	90.31M	116M	126M	120M
Research And Development Expense From Footnotes	230M	420M	435M	466M	389M
Net Rental Expense, Total	16.24M	22.47M	33.4M	37.51M	64.41M
Stock-Based Comp., COGS (Total)	26.71M	56.28M	82.21M	94.23M	49.44M
Stock-Based Comp., G&A Exp. (Total)	20.3M	35.12M	51.84M	60.04M	30.78M
Total Stock-Based Compensation	47.01M	91.4M	134M	154M	80.22M

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	123M	524M	227M	189M	155M
Short Term Investments	625M	669M	685M	412M	294M
Total Cash And Short Term Investments	749M	1.19B	912M	602M	450M
Accounts Receivable, Total	2.03M	3.77M	36.46M	8.52M	9.47M
Total Receivables	2.03M	3.77M	36.46M	8.52M	9.47M
Prepaid Expenses	18.58M	20.41M	47.55M	29.83M	68.36M
Restricted Cash	-	-	-	-	-
Other Current Assets, Total	-	-	2.1M	-	-
Total Current Assets	769M	1.22B	998M	640M	528M
Gross Property Plant And Equipment	126M	194M	188M	296M	182M
Accumulated Depreciation	-26.11M	-33.2M	-39.86M	-49.69M	-58.61M
Net Property Plant And Equipment	100M	161M	148M	247M	124M
Long-term Investments	420M	127M	136M	287M	178M
Other Long-Term Assets, Total	4.76M	15.73M	18.08M	17.39M	13.08M
Total Assets	1.29B	1.52B	1.3B	1.19B	842M
Liabilities
Accounts Payable, Total	9.65M	5.15M	7.45M	14.59M	20.25M
Accrued Expenses, Total	43.31M	60.88M	60.13M	55.36M	49.86M
Current Portion of Leases	9.11M	16.68M	18.6M	20.25M	26.48M
Unearned Revenue Current, Total	63.76M	43.84M	22.14M	20.66M	7.29M
Other Current Liabilities	-	-	6.89M	-	-
Total Current Liabilities	126M	127M	115M	111M	104M
Long-Term Leases	64.91M	114M	96.75M	190M	66.85M
Unearned Revenue Non Current	63.48M	19.93M	38.85M	18.26M	-
Other Non Current Liabilities	-	24.03M	-	-	-
Total Liabilities	254M	285M	251M	319M	171M
Common Stock, Total	7K	9K	9K	10K	12K
Additional Paid In Capital	1.75B	2.42B	2.71B	3.05B	3.26B
Retained Earnings	-703M	-1.18B	-1.66B	-2.18B	-2.59B
Comprehensive Income and Other	-2.63M	-7.46M	-2.26M	605K	1.03M
Total Common Equity	1.04B	1.24B	1.05B	872M	671M
Total Equity	1.04B	1.24B	1.05B	872M	671M
Total Liabilities And Equity	1.29B	1.52B	1.3B	1.19B	842M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	74.67M	88.02M	96.11M	104M	118M
ECS Total Common Shares Outstanding	74.49M	87.1M	93M	102M	116M
Book Value / Share	13.97	14.19	11.29	8.55	5.77
Tangible Book Value	1.04B	1.24B	1.05B	872M	671M
Tangible Book Value Per Share	13.97	14.19	11.29	8.55	5.77
Total Debt	74.02M	131M	115M	210M	93.33M
Net Debt	-1.01B	-1.13B	-897M	-652M	-512M
Debt Equivalent Oper. Leases	130M	180M	267M	300M	515M
Equity Method Investments, Total	58.13M	32.46M	11.76M	-	-
Account Code - Inventory Valuation	3	3	3	3	3
Machinery, Total	43.34M	56.33M	67.58M	71.97M	71.16M
Full Time Employees	485	598	526	403	377

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	-268M	-474M	-481M	-519M	-413M
Depreciation & Amortization - CF	6.89M	7.57M	8.98M	10.28M	15.92M
Depreciation & Amortization, Total	6.89M	7.57M	8.98M	10.28M	15.92M
(Gain) Loss From Sale Of Asset	-	-162K	72K	-76K	527K
(Gain) Loss on Sale of Investments - (CF)	10.54M	15.41M	-19.27M	-6.22M	-4.96M
Asset Writedown & Restructuring Costs	-	55.99M	-	-	-
(Income) Loss On Equity Investments - (CF)	1.32M	11.08M	15.63M	-	-
Stock-Based Compensation (CF)	47.01M	91.4M	134M	154M	80.22M
Other Operating Activities, Total	-	13.48M	100K	-	-
Change In Accounts Receivable	99K	-1.74M	-32.69M	27.94M	-951K
Change In Accounts Payable	529K	-4.58M	2.52M	6.8M	5.99M
Change in Unearned Revenues	-31.36M	-63.46M	-2.78M	-22.08M	-28.11M
Change in Other Net Operating Assets	7.82M	15.91M	-19.51M	-785K	-50.68M
Cash from Operations	-225M	-333M	-394M	-349M	-395M
Capital Expenditure	-12.76M	-13.56M	-13.98M	-5.78M	-1.13M
Sale of Property, Plant, and Equipment	-	150K	-	-	-
Sale (Purchase) of Intangible assets	-	-44.83M	-	-	-
Investment in Marketable and Equity Securities, Total	-538M	219M	-17.36M	131M	229M
Cash from Investing	-551M	160M	-31.35M	126M	228M
Issuance of Common Stock	737M	583M	130M	186M	131M
Other Financing Activities, Total	-	-	-	-	-
Cash from Financing	737M	583M	130M	186M	131M
Net Change in Cash	-39.12M	410M	-295M	-37.57M	-35.22M
Supplemental Items
Levered Free Cash Flow	-63.32M	-256M	-268M	-133M	-233M
Unlevered Free Cash Flow	-63.32M	-256M	-268M	-133M	-233M
Change In Net Working Capital	-56.69M	10.41M	75.19M	-41.76M	52.68M

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	-16.35	-20.35	-22.83	-26.8	-27.11
Return on Total Capital	-19.18	-23.09	-25.44	-29.71	-29.85
Return On Equity %	-34.18	-41.67	-42.1	-54	-53.48
Return on Common Equity	-34.18	-41.67	-42.1	-54	-53.48
Margin Analysis
Gross Profit Margin %	-565.01	-705.78	-1.1K	-705.69	-379.46
SG&A Margin	215.1	173.26	321.15	217.41	272.21
EBITDA Margin %	-759.26	-864.51	-1.4K	-905.33	-637.23
EBITA Margin %	-780.11	-879.04	-1.42K	-923.1	-651.67
EBIT Margin %	-780.11	-879.04	-1.42K	-923.1	-651.67
Income From Continuing Operations Margin %	-810.49	-909.78	-1.33K	-896.77	-609.85
Net Income Margin %	-810.49	-909.78	-1.33K	-896.77	-609.85
Net Avail. For Common Margin %	-810.49	-909.78	-1.33K	-896.77	-609.85
Normalized Net Income Margin	-487.65	-552.44	-828.9	-525.31	-380.33
Levered Free Cash Flow Margin	-191.57	-491.51	-739.37	-230.45	-344.74
Unlevered Free Cash Flow Margin	-191.57	-491.51	-739.37	-230.45	-344.74
Asset Turnover
Asset Turnover	0.03	0.04	0.03	0.05	0.07
Fixed Assets Turnover	0.43	0.4	0.23	0.29	0.37
Receivables Turnover (Average Receivables)	15.89	17.98	1.8	2.57	7.53
Short Term Liquidity
Current Ratio	6.11	9.61	8.67	5.77	5.08
Quick Ratio	5.97	9.45	8.23	5.5	4.42
Operating Cash Flow to Current Liabilities	-1.79	-2.63	-3.42	-3.15	-3.8
Days Sales Outstanding (Average Receivables)	22.97	20.3	202.37	142.2	48.5
Average Days Payable Outstanding	16.7	6.43	5.29	8.65	19.6
Long Term Solvency
Total Debt/Equity	7.12	10.58	10.98	24.11	13.9
Total Debt / Total Capital	6.64	9.57	9.9	19.42	12.2
LT Debt/Equity	6.24	9.23	9.21	21.78	9.96
Long-Term Debt / Total Capital	5.83	8.34	8.3	17.55	8.74
Total Liabilities / Total Assets	19.64	18.72	19.28	26.79	20.27
Total Debt / EBITDA	-0.32	-0.31	-0.24	-0.43	-0.25
Net Debt / EBITDA	4.31	2.64	1.9	1.34	1.4
Total Debt / (EBITDA - Capex)	-0.3	-0.3	-0.24	-0.43	-0.25
Net Debt / (EBITDA - Capex)	4.09	2.56	1.84	1.32	1.39
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-43.01	57.69	-30.4	59.55	16.92
Gross Profit, 1 Yr. Growth %	102.08	86.96	8.41	2.42	-26.43
EBITDA, 1 Yr. Growth %	92.64	72.67	12.37	3.49	-17.7
EBITA, 1 Yr. Growth %	88.79	71.05	12.47	3.68	-17.46
EBIT, 1 Yr. Growth %	88.79	71.05	12.47	3.68	-17.46
Earnings From Cont. Operations, 1 Yr. Growth %	99.58	77.01	1.48	7.86	-20.49
Net Income, 1 Yr. Growth %	99.58	77.01	1.48	7.86	-20.49
Normalized Net Income, 1 Yr. Growth %	92.13	71.97	4.43	1.11	-15.35
Diluted EPS Before Extra, 1 Yr. Growth %	57.61	63.03	-12.01	-3.14	-27.48
Accounts Receivable, 1 Yr. Growth %	-4.65	85.52	867.52	-76.64	11.17
Net Property, Plant and Equip., 1 Yr. Growth %	81.83	60.82	-7.99	66.52	-49.88
Total Assets, 1 Yr. Growth %	91.4	17.43	-14.42	-8.45	-29.29
Tangible Book Value, 1 Yr. Growth %	97.36	18.78	-15.01	-16.97	-23
Common Equity, 1 Yr. Growth %	97.36	18.78	-15.01	-16.97	-23
Cash From Operations, 1 Yr. Growth %	350.85	48.11	18.24	-11.47	13.14
Capital Expenditures, 1 Yr. Growth %	255.82	6.29	3.15	-58.68	-80.46
Levered Free Cash Flow, 1 Yr. Growth %	45.71	268.25	4.69	-50.27	74.9
Unlevered Free Cash Flow, 1 Yr. Growth %	45.71	268.25	4.69	-50.27	74.9
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	-12.43	-5.2	4.76	5.38	36.58
Gross Profit, 2 Yr. CAGR %	69.1	99.51	42.37	5.37	-19.76
EBITDA, 2 Yr. CAGR %	57.8	85.98	39.29	7.84	-7.71
EBITA, 2 Yr. CAGR %	55.7	83.15	38.7	7.99	-7.49
EBIT, 2 Yr. CAGR %	55.7	83.15	38.7	7.99	-7.49
Earnings From Cont. Operations, 2 Yr. CAGR %	64.06	87.95	34.02	4.62	-7.39
Net Income, 2 Yr. CAGR %	64.06	87.95	34.02	4.62	-7.39
Normalized Net Income, 2 Yr. CAGR %	60.97	85.26	34.01	2.76	-7.48
Diluted EPS Before Extra, 2 Yr. CAGR %	33.93	60.3	19.77	-7.68	-16.19
Accounts Receivable, 2 Yr. CAGR %	-33.7	33	323.67	50.34	-49.04
Net Property, Plant and Equip., 2 Yr. CAGR %	64.2	71	21.64	23.78	-8.65
Total Assets, 2 Yr. CAGR %	96.78	49.92	0.25	-11.48	-19.54
Tangible Book Value, 2 Yr. CAGR %	96.33	53.11	0.48	-15.99	-20.04
Common Equity, 2 Yr. CAGR %	96.33	53.11	0.48	-15.99	-20.04
Cash From Operations, 2 Yr. CAGR %	47.64	158.41	32.34	2.31	0.08
Capital Expenditures, 2 Yr. CAGR %	37.02	94.47	4.71	-34.72	-71.59
Levered Free Cash Flow, 2 Yr. CAGR %	0.96	142.8	96.35	-27.84	-6.74
Unlevered Free Cash Flow, 2 Yr. CAGR %	0.96	142.8	96.35	-27.84	-6.74
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	2.79	6.54	-14.48	20.53	9.09
Gross Profit, 3 Yr. CAGR %	47.09	77.92	62.81	27.57	-11.29
EBITDA, 3 Yr. CAGR %	42.68	64.74	57.23	26.16	-1.45
EBITA, 3 Yr. CAGR %	41.57	62.71	55.67	25.88	-1.27
EBIT, 3 Yr. CAGR %	41.57	62.71	55.67	25.88	-1.27
Earnings From Cont. Operations, 3 Yr. CAGR %	46.42	68.26	53.05	24.66	-4.52
Net Income, 3 Yr. CAGR %	46.42	68.26	53.05	24.66	-4.52
Normalized Net Income, 3 Yr. CAGR %	44.57	66.65	53.04	22	-3.67
Diluted EPS Before Extra, 3 Yr. CAGR %	24.01	43	31.25	11.59	-14.82
Accounts Receivable, 3 Yr. CAGR %	-35.44	-6.57	157.71	61.26	35.95
Net Property, Plant and Equip., 3 Yr. CAGR %	80.37	63.06	39.09	35.07	-8.43
Total Assets, 3 Yr. CAGR %	55.04	65.67	24.37	-2.74	-17.87
Tangible Book Value, 3 Yr. CAGR %	55.26	66.05	25.83	-5.71	-18.4
Common Equity, 3 Yr. CAGR %	55.26	66.05	25.83	-5.71	-18.4
Cash From Operations, 3 Yr. CAGR %	54.3	47.79	99.13	15.74	5.8
Capital Expenditures, 3 Yr. CAGR %	26.12	25.9	57.42	-23.2	-56.33
Levered Free Cash Flow, 3 Yr. CAGR %	29.44	60.37	83.43	24.23	-3.07
Unlevered Free Cash Flow, 3 Yr. CAGR %	29.44	60.37	83.43	24.23	-3.07
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	14.94	14.82	3.57	6.07	3.13
Gross Profit, 5 Yr. CAGR %	64.8	54.69	46.71	44.29	22.68
EBITDA, 5 Yr. CAGR %	51.88	46.59	42.42	39.06	27.05
EBITA, 5 Yr. CAGR %	51.64	45.79	41.49	38.1	26.42
EBIT, 5 Yr. CAGR %	51.64	45.79	41.49	38.1	26.42
Earnings From Cont. Operations, 5 Yr. CAGR %	53.31	47.66	41.33	39.14	25.19
Net Income, 5 Yr. CAGR %	53.31	47.66	41.33	39.14	25.19
Normalized Net Income, 5 Yr. CAGR %	52.14	46.81	41.32	37.35	25.13
Diluted EPS Before Extra, 5 Yr. CAGR %	21.56	26.85	22.3	20.04	9.69
Accounts Receivable, 5 Yr. CAGR %	-20.64	-18.49	37.02	13.01	34.76
Net Property, Plant and Equip., 5 Yr. CAGR %	56.61	60.17	54.07	46.04	17.56
Total Assets, 5 Yr. CAGR %	34.06	32.22	30.23	28.93	4.48
Tangible Book Value, 5 Yr. CAGR %	37.74	32.67	30.46	26.43	4.96
Common Equity, 5 Yr. CAGR %	37.74	32.67	30.46	26.43	4.96
Cash From Operations, 5 Yr. CAGR %	44.19	38.55	45.11	27.58	51.22
Capital Expenditures, 5 Yr. CAGR %	15.65	6.08	17.08	-3.19	-20.63
Levered Free Cash Flow, 5 Yr. CAGR %	67.22	44.6	55.82	16.51	39.95
Unlevered Free Cash Flow, 5 Yr. CAGR %	67.22	44.6	55.82	16.51	39.95